Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology NPS & Customer Reviews | Comparably
PumaBiotech (@pumabiotech) / Twitter
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma Biotechnology Inc Share Price USD0.0001
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech plunges on drug side effects
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology, Inc.
Puma Biotechnology
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
